Whitehawk Therapeutics (WHWK) Amortization of Deferred Charges (2016 - 2023)

Whitehawk Therapeutics (WHWK) has reported Amortization of Deferred Charges for 7 consecutive years, with -$38000.0 the latest figure, recorded in Q4 2024.

• In Q4 2024, Amortization of Deferred Charges changed N/A year-over-year to -$38000.0; the TTM figure through Sep 2025 stood at -$38000.0 (down 200.0% YoY), while the FY2023 annual figure was $58000.0, changed N/A from the prior year.
• Amortization of Deferred Charges declined to -$38000.0 in Q4 2024 per WHWK's latest filing, from -$20000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $230000.0 in Q4 2020 and bottomed at -$584000.0 in Q4 2021.
• Historically, Amortization of Deferred Charges has averaged $24000.0 across 5 years, with a median of $58000.0 in 2022.
• Annual changes were most pronounced in 2021 — Amortization of Deferred Charges sank 353.91% — and 2023, when it changed 0.0%.
• Whitehawk Therapeutics' Amortization of Deferred Charges stood at $230000.0 in 2020, then slumped by 353.91% to -$584000.0 in 2021, then soared by 80.31% to -$115000.0 in 2022, then jumped by 150.43% to $58000.0 in 2023, then plunged by 165.52% to -$38000.0 in 2024.
• Business Quant data shows WHWK's Amortization of Deferred Charges at -$38000.0 in Q4 2024, -$20000.0 in Q3 2024, and $58000.0 in Q1 2024.